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Parathyroid hormone, prolactin, and function of the pituitary-gonadal
axis in male patients with acute renal failure. In 26 patients with acute
renal failure (ARF), plasma levels of lutropin (LH), folitropin (FSH),
prolactin, testosterone, estradiol, and parathyroid hormone (PTH) were
studied at the anuric/oliguric (AOP) and polyuric phase. Significantly
elevated levels of LH, FSH, and prolactin were found during the AOP.
Administration of luliberin (LH-RH) was followed by a normal or even
excessive and prolonged increase of plasma LH and FSH levels during
the AOP. Basal plasma testosterone was significantly depressed, but
estradiol was moderately elevated at the AOP. Administration of LH-
RH did not influence significantly either testosterone or estradiol levels
in blood plasma. A negative correlation was found between plasma
prolactin and testosterone, and a positive one was found between
prolactin and estradiol at the AOP of ARF. In contrast to chronic renal
failure, PTH was not significantly correlated with either plasma testos-
terone or prolactin. We conclude that the hyporesponsiveness of
Leydig's cell to the LH signal is the cause of depressed testosterone
biosynthesis. It seems probable that prolactin, but not PTH, is involved
in the pathogenesis of testicular dysfunction in patients with ARF.
L'hormone parathyroIdienne, Ia prolactine, et Ia fonction de l'axe
hypophyso.gonadal chez des patients males avec un échec renal aigu. On a
étudié chez 26 patients avec un échec renal aigu (ARF) les niveaux
plasmatiques de Ia lutropine (LH), folitropine (FSH), prolactine, testos-
térone, estradiole, et l'hormone parathyroidlenne (PTH) a La phase anu-
rique/oligurique (AOP) et polyurique. On a trouvé des niveaux significa-
tivement élevés de LH, FSH, et de La prolactine pendant Ia phase AOP.
L'administration de luliberine (LH-RH) a etC suivie par des augmenta-
tions normales ou mCme excessives et prolongees de niveaux plasma-
tiques de LH et FSH pendant AOP. La testosterone plasmatique basale
Ctait diminuCe d'une facon significative rnais l'estradiole etait ClevCe
modCrement. L'administration de LH-RH n'a pas influence de maniCre
significative nile niveau de La testosterone nile niveau de l'estradiole
dans Ia plasma sanguin. On a trouvC une correlation negative entre
prolactine plasmatique et Ia testosterone et une correlation positive
entre In prolactine et l'estradiole a AOP de ARF. PTH, faisant contraste
avec L'échec renal chronique, ne se trouvait en correlation ni avec Ia
testosterone plasmatique ni avec Ia prolactine. Nous en concluons que
l'hypersensibilitC de La cellule de Leydig au signal LH provoque
l'abaissement de La biosynthese de Ia testosterone. II est probable que Ia
prolactine, mais non PTH, a un role dans Ia pathogenese du dysfonc-
tionnement du testicule chez les patients avec ARF.
The existence of hypogonadism in patients with chronic renal
failure is now well known [1—4]. Parathyroid hormone (PTH),
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as a presumed uremic toxin [5—7], and prolactin [7, 8] have been
incriminated as the agents causing decreased testosterone se-
cretion and poor spermatogenesis in these patients. In contrast
to chronic renal failure, function of the pituitary-gonadal axis in
acute renal insufficiency (ARF) has not yet been studied
systematically. Thus, we examined endocrine gonadal function
in male patients with ARF in relation to the particular phases of
84
this syndrome and to PTH and prolactin secretion.
Methods
Twenty-six male patients were examined during the anuric/
oliguric phase (AOP) (diuresis, < 500 mI/day) and polyuric
phase (PP) (diuresis, > 1500 mI/day) of ARF. The mean age of
patients was 34.6 years (range, 20 to 56 years). The causes of
ARF are enumerated in Table I. Lutropin (LH), folitropin
(FSH), prolactin, testosterone, and estradiol were estimated in
blood serum obtained before (0) and 20, 30, 60, and 120 mm
after an i.v. bolus injection of 100 pg of luliberin (LH-RH;
Hoechst, FRG). In addition, PTH and creatinine were deter-
mined in blood serum obtained only at the beginning of the
above-mentioned tests. All examinations were performed in
fasted patients in the morning, immediately before the hemodi-
alysis procedure. All patients were hemodialyzed every 2 to 3
days, using the coil dialyzer of Bellco, and with a calcium
concentration of 1.75 mmoles/liter in the dialysate. A diet with a
protein concentration of 1 g/kg of body wt was supplied.
FSH and LH were estimated by radioimmunoassay using a
double-antibody technique [9]. Pure LH and FSH for iodination
and antisera to LH and FSH were obtained from Calbiochem
(La Jolla, California). The International Reference Preparation
for Human Menopausal Gonadotropin (IRP-HMG), obtained
from the Department of Biological Standards, National Institute
for Medical Research, Mill Hill, London NW7, England, was
used as the reference preparation. The assay sensivity for these
hormones was 0.12 mIU/tube. The intraassay and interassay
variations for LH were 8% and 15%, and for FSH they were 7%
and 16%, respectively.
Prolactin was assessed by a radioimmunoassay using a dou-
ble-antibody technique [9]. Pure antigen (with a biological
activity of 20 to 25 lU/mg), obtained from Kabi, Stockholm,
Sweden, was used for iodination and preparation of the stan-
dard curve. Highly specific antibodies were kindly supplied by
Dr. W. Jeske, Department of Endocrinology, Postgraduate
Medical School, Warsaw, Poland. The assay sensitivity for
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Table 1. Causes of acute renal failure
Cause No. of cases
Acute glomerulonephritis
Crush syndrome
Toxic shock/post medicamentous/
Hypovolemic shock
Septic shock
Carbon tetrachioride intoxication
Trichlorethylene intoxication
Leptospirosis
Unknown cause
Total
6
5
5
2
3
1
I
I
3
26
prolactin was 1.1 ng/ml of plasma, and the intraassay and
interassay variations were 8% and 17%, respectively.
The serum immunoreactive parathyroid hormone (PTH) was
measured by radioimmunoassay [9] using highly purified bovine
PTH (Wilson Pharmaceutical and Chemical Corporation, Par
Forest South, Illinois) as a standard and '251-bovine PTH as the
tracer. The antiserum (elaborated in our laboratory) used was
heterogenous and was shown to combine with N-terminal and
C-terminal antigenic determinants. The detection limit was 50
pg/assay tube, and the intraassay and interassay variations were
15% and 21%, respectively. In normal subjects, the level of
serum PTH was less than 0.6 gig/liter.
Testosterone and estradiol were estimated by radio-
immunoassay [9]. The tritiated hormones were obtained from
Amersham, England; and highly purified testosterone and es-
tradiol for preparation of the standard curves, from Caibjo-
chem, Lucerne, Switzerland. Highly specific antibodies were
kindly supplied by Dr. Stupnicki (Department of Animal Physi-
ology, Polish Academy of Science, Warsaw). The assay sensi-
tivity for testosterone was 30 pg/assay tube, and the intraassay
and interassay variations were 8% and 9%, respectively. The
sensitivity for estradiol was 4 pg/assay tube, and the intraassay
variations were 8% and 11%, respectively.
Creatinine concentration was estimated by the Jaffe reaction
[10].
Results obtained in patients with ARF were compared with
those of 16 healthy male subjects with a mean age of 30.3 years
(range, from 20 to 45 years).
Statistical analysis was performed using Student's t test.
Results
The mean serum creatinine concentration at the AOP was
1246 87 imo1es/liter; but at the PP, it was 346 lJ.moles/liter.
As can be seen in Fig. 1, LH levels in patients with ARF were
significantly elevated during the AOP, displaying an excessive
and prolonged increase after LH-RH stimulation. At the PP, at
0 and 120 mm, LH levels were still significantly increased as
compared with control subjects, but the LH curve was similar
to that of control group.
Plasma FSH concentrations were significantly increased,
only during the PP of ARF at 0 and 120 mm of the LH-RH test.
As shown in Fig. 2, LH-RH administration was followed by a
normal but prolonged increase of FSH in blood plasma.
Significantly elevated plasma levels of prolactin were found
in both phases of ARF (Fig. 3). Only at the AOP did a moderate
(but statistically not significant) increase of plasma prolactin
concentration occur after LH-RH administration.
Significantly depressed testosterone levels were found in
blood plasma of patients with ARF at the AOP (Fig. 4). These
levels were at the lower normal range at the PP. No significant
increase of plasma testosterone occurred after LH-RH adminis-
tration either in patients or in healthy subjects.
Moderately elevated basal levels of plasma estradiol occurred
at the AOP of ARF, which decreased at the PP below the mean
normal range (Fig. 5). LH-RH administration did not influence
the plasma concentration of this hormone either in healthy
subjects or in patients.
A statistically positive correlation was found between plasma
LH and testosterone levels in healthy subjects (r = 0.46, P <
0.05). This corrrelation could not be demonstrated in patients
with ARF at either the AOP or the PP.
In contrast to healthy subjects, a significantly negative corre-
lation (r = 0.34, P < 0.01) was found between plasma prolactin
and testosterone levels at the AOP of ARF patients (Fig. 6).
This correlation was absent at the PP.
Interestingly, a significant positive correlation was found
between plasma prolactin and estradiol levels (r 0.55, P <
0.01) in patients with ARF at the AOP (Fig. 7). Such a
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Fig. 1. Influence of LH-RH onplasma levels of LH in patients with ARF
at the oliguric/anuric (AOP) and polyuric (PP) phase and in healthy
subjects (N). Means SCM. The degree of statistical significance
concerns the difference between corresponding means obtained in
healthy subjects and patients. Probabilities are denoted by V, P < 0.05;
x, P <0.02; y, P <0.01; z, P <0.001.
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correlation could not be proven for healthy subjects and pa-
tients with ARF at the PP.
As can be seen in Fig. 8, moderately increased levels of PTH
in blood serum were found at the AOP in the majority of
patients with ARF. No significant correlation was found be-
tween PTH and testosterone levels neither during the AOP nor
PPofARF.
No significant correlation could be documented between
plasma prolactin and PTH levels.
Discussion
Among the endocrine abnormalities we found in patients with
ARF, the following are to be stressed: elevated LH and
prolactin levels, significantly lowered testosterone levels, ab-
sence of the physiologic correlation between plasma LH and
testosterone levels in blood plasma, presence of a negative
correlation between plasma prolactin and testosterone levels,
and presence of a positive correlation between plasma prolactin
and estradiol levels.
The kidneys are important organs involved in the elimination
and biodegradation of gonadotropin [11], prolactin [12, 13], and
PTH [14, 15]. Therefore, it seems quite possible that impaired
renal clearance of these hormones could contribute to their
elevation in blood plasma in ARF. This explanation seems
barely true for FSH and LH for the following two reasons: (1)
In contrast to chronic renal insufficiency, renal blood flow is
relatively well preserved in patients with ARF; the reduction of
renal blood flow is usually not greater than 30 to 50% [16, 17].
Therefore, depression of renal elimination and/or biodegrada-
tion of the hormones in question seems not lobe the main factor
responsible for the observed hormonal abnormalities. (2) Con-
sidering the biological tV2 of FSH, which is about 3 to 4 hours
[18], and of LH, which is about 50 mm [19], and assuming that
the impaired renal elimination and/or biodegradation are the
main causes of elevated plasma gonadotropin levels, we expect-
ed higher FSH than LH levels in blood plasma in ARF during
the anuric/oliguric phase. Such differences were not found in
our studies. Moreover, contrary to our expectation, higher FSH
levels occurred at the polyuric phase. From the above, it
follows that enhanced levels of FSH and LH in patients with
ARF are evoked by abnormal hormone secretion rather than by
their elimination.
Significantly elevated LH levels in the presence of low
plasma testosterone concentrations suggest that, in patients
with ARF, the negative feedback effect of testosterone on the
hypothalamus is intact. Similar to observations in patients with
chronic renal failure [20], the administration of LH-RH was
followed by a normal or even excessive and prolonged increase
of gonadotropin in blood plasma, proving the presence of
normal reactivity of the pituitary gonadotrophs to hypothalamic
stimuli. But the absence of the physiologic positive correlation
between plasma LH and testosterone levels in anuric/oliguric
patients with ARF, as well as the presence of low plasma
concentrations of testosterone despite high levels of LH, sug-
gests the existence of hyporesponsiveness and or abnormal
reactivity of Leydig's cell to LH-RH. This hypothesis seems to
be supported by the results of our studies performed in patients
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Fig. 2. influence of LH-RH on plasma levels of FSH in patients with
ARF at the oliguriclanuric (AOP) and polyuric (PP) phase and healthy
subjects (N). Means SEM. For other symbols, see Fig. 1.
N
20 30 60 120
Time, mm
Fig. 3. influence of LH-RH on plasma levels of prolac/in in patients
with ARF at the oliguric/anuric (AOP) and polyuric (PP) phase and in
healthy subjects (N). Means SEM. For other symbols, see Fig. 1.
with ARF, in which no increase of testosterone secretion was
found after the administration of chorionic gonadotropin (un-
published).
As already mentioned, kidneys seem to be involved in the
elimination of prolactin from blood [12, 13] although unequivo-
cal results were not obtained [211. When we calculated the
disappearance rate of plasma prolactin in patients with ARF
after oral aipha-bromocriptine administration, we found normal
or even increased values [22]. These findings support the
hypothesis that increased prolactin secretion rather than im-
paired renal elimination is involved in the pathogenesis of
elevated prolactin levels in blood plasma of patients with ARF.
Among factors stimulating prolactin secretion are estrogens and
PTH. As shown by other authors, treatment with estrogens not
only stimulates basal prolactin secretion but also can reverse
the inhibitory effects of dopamine on prolactin secretion in vivo
and in vitro [23]. Also endogenous and exogeneous PTH
produces a rapid and marked increase of plasma prolactin in
normal subjects [24]. As significant, elevated, basal concentra-
tions of estradiol were found at the anuric/oliguric phase, which
were positively correlated to plasma prolactin levels, involve-
ment of estrogens in enhanced prolactin secretion in patients
with ARF is very suggestive. The same seems to be true for
PTH, despite lack of significant correlation between plasma
PTH and prolactin levels. This does not exclude the involve-
ment of other factors in the pathogenesis of the described
hormonal abnormalities.
As a negative correlation was found between prolactin and
testosterone levels, it seems possible that prolactin may be
involved in the pathogenesis of testicular dysfunction in ARF.
This likewise does not exclude other factors or "uremic toxins"
in the pathomechanism of impaired testosterone secretion in
ARF.
The mechanism of enhanced basal estradiol levels in patients
with ARF at the anuric/poliuric phase remains to be elucidated.
PTH secretion in patients with ARF was discussed in one of
our previous papers [14]. From these studies we concluded that
enhanced PTH levels in ARF are not only evoked by abnormali-
ties of the existing calcium phosphate metabolism and impaired
renal excretory function but also by other factors.
In our present studies, no correlation was found between
plasma PTH and plasma prolactin or testosterone levels. These
findings are contrast with the findings in patients with chronic
renal failure, in whom enhanced PTH secretion seems to be an
important factor in the pathogenesis of hyperprolactinemia and
depressed testosterone secretion [5, 71. Moreover, our present
results seem to prove the absence of the physiologic feedback
between PTH and prolactin secretion [24] in acutely uremic
patients. And from our results it follows that PTH should not be
incriminated yet as a uremic toxin involved in the pathogenesis
of hypogonadism in patients with ARF, which is in contrast to
chronic renal failure.
Conclusion. The observed endocrine abnormalities in pa-
tients with ARF suggest the presence of hyporeactivity of
Leydig's cell to the stimulatory effect of lutropin. Prolactin
seems to be involved in the pathogenesis of testicular dysfunc-
tion in ARF. And, in contrast to chronic renal failure, PTH may
not be involved in the pathogenesis of gonadal dysfunction of
ARF, or if it is, it is not proven.
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Fig. 4. Influence of LH-RH on plasma levels of testosterone in patients
with ARF at the oliguriclanuric (AOP) and polvuric (PP) phase and in
healthy subjects (N). Means SEM. For other symbols, see Fig. I - 0 20 30 60 120
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Fig. 5. Influence of LH-RH on plasma levels of estradiol in patients
with ARF at the oliguriclanuric (AOP) and polyuric (PP) phase and in
healthy subjects (N). Means SEM. For other symbols, see Fig. I.
Fig. 7. Correlation between plasma prolactin and estradiol levels in
patients with ARF at the anuric/oliguric phase during the LH-RH. For
other symbols, see Fig. 1.
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